However, in view of the very early onset of CF organ disease it was evident that ETI therapy should be offered to younger children and ultimately infants to tackle and prevent the sequelae of CFTR dysfunction (VanDevanter et al., 2016). This evidence concerns the gene CFTR and cystic fibrosis.